CABA vs. OPK, BEAM, FUSN, SANA, NMRA, VIR, CGEM, BCRX, TARS, and FDMT
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include OPKO Health (OPK), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), Cullinan Therapeutics (CGEM), BioCryst Pharmaceuticals (BCRX), Tarsus Pharmaceuticals (TARS), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "medical" sector.
Cabaletta Bio (NASDAQ:CABA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Cabaletta Bio has higher earnings, but lower revenue than OPKO Health. Cabaletta Bio is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
Cabaletta Bio has a net margin of 0.00% compared to OPKO Health's net margin of -31.44%. OPKO Health's return on equity of -17.89% beat Cabaletta Bio's return on equity.
OPKO Health received 421 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 70.00% of users gave Cabaletta Bio an outperform vote while only 65.70% of users gave OPKO Health an outperform vote.
Cabaletta Bio currently has a consensus target price of $34.33, suggesting a potential upside of 236.93%. OPKO Health has a consensus target price of $3.17, suggesting a potential upside of 131.14%. Given Cabaletta Bio's higher possible upside, equities analysts plainly believe Cabaletta Bio is more favorable than OPKO Health.
64.6% of OPKO Health shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by company insiders. Comparatively, 47.3% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, OPKO Health had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for OPKO Health and 4 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat OPKO Health's score of 0.26 indicating that Cabaletta Bio is being referred to more favorably in the media.
Cabaletta Bio has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.
Summary
OPKO Health beats Cabaletta Bio on 9 of the 16 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
